Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CISD2 | Q8N5K1 | 2/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15822374 | 0.87 | CYP3A4 (0.47) | CYP3A4ACHEHPGDPOLBGAA | |
| SCHEMBL1036031 | 0.82 | CYP3A4 (0.59) | CYP3A4ACHEHPGDPOLBGAA | |
| SCHEMBL2892585 | 0.81 | CYP3A4 (0.36) | CYP3A4ACHEHPGDPOLBGAA | |
| SCHEMBL70139 | 0.80 | CYP3A4 (0.57) | CYP3A4ACHEHPGDPOLBGAA | |
| SCHEMBL197898 | 0.80 | CYP3A4 (0.81) | CYP3A4ACHEHPGDPOLBGAA | |
| SCHEMBL10535950 | 0.80 | KDM4E (0.47) | CYP3A4ACHEHPGDPOLBGAA | |
| SCHEMBL11215789 | 0.79 | CYP3A4 (0.58) | CYP3A4HPGDGAACA12CA1 | |
| SCHEMBL11067587 | 0.78 | CYP3A4 (0.79) | CYP3A4ACHEHPGDPOLBGAA | |
| SCHEMBL610098 | 0.78 | CYP3A4 (0.55) | CYP3A4ACHEHPGDPOLBCA12 | |
| SCHEMBL19731519 | 0.78 | CYP3A4 (0.55) | CYP3A4ACHEHPGDPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57109752-A | — | — | None | — | — | JP | disclosed |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| EP-1632479-B1 | Pharmaceutical compositions comprising CCR5 antagonizing piperazine derivatives | SCHERING CORP (US) | 2011-01-12 | — | — | EP | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| WO-2007050375-A2 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
| JP-S57109752-A | NOVEL 4-AMINO-2,6-DIALKYL-3-NITROBENZOIC ACID ALKYL ESTER DERIVATIVE | ISHIKAWA MASAYUKI | 1982-07-08 | — | — | JP | disclosed |
| EP-0035393-A1 | Poultry feeds containing and methods of using anovulatory compounds, and novel anovulatory imidazolines | MERCK & CO. INC. (US) | 1981-09-09 | — | — | EP | disclosed |
| US-4288438-A | Nitrogen-containing heterocyclic ring derivatives and analgesic and anti-inflammatory compositions and methods employing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1981-09-08 | — | — | US | disclosed |
| US-4287201-A | CONTAINING A 2-(SUBSTITUTED PHENYLIMINO)IMIDAZOLIDINE COMPOUND | MERCK & CO., INC. (US) | 1981-09-01 | — | — | US | disclosed |
| US-4284778-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1981-08-18 | — | — | US | disclosed |
| US-4251533-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1981-02-17 | — | — | US | disclosed |
| US-4186200-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | CYP3A4 3725/4885ACHE 1667/4885HPGD 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.